MINI FUTURE SHORT - ELI LILLY & CO | Real-time Euronext Paris 07:48:40 16/07/2024 pm IST | ||
| 4.312 EUR | +2.11% |
|
| Current month | -16.72% | ||
| 1 month | -24.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 4.312 | +2.11% |
| 15/24/15 | 4.223 | -3.76% |
| 12/24/12 | 4.388 | -7.05% |
| 11/24/11 | 4.721 | +7.15% |
| 10/24/10 | 4.406 | -8.06% |
Real-time Euronext Paris
Last update July 16, 2024 at 07:48 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| X75OB | |
| ISIN | NLBNPNL2SW59 |
| Date issued | 12/06/2024 |
| Strike | 1,183 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 5.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.985 € |
|---|---|
| Lowest since issue | 4.001 € |
| Spread | 0.024 € |
| Spread % | 0.57% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Certificates
- X75OB Certificat
